CRVO
What one share of CervoMed holds
Pharmaceutical Preparations
We are a clinical-stage biotechnology company developing treatments for age-related brain disorders. Our lead drug candidate, neflamapimod, is an investigational, orally administered small-molecule drug that readily crosses the blood brain barrier and selectively inhibits the enzyme p38α, a key driver of neuroinflammation and synaptic dysfunction.
CervoMed’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.03 |
|---|---|
| Profit | −$3.19 |
| Cash and investments | $1.84 |
| Book value | $1.70 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | — | −$1,322 | $0.17 | −$789.42 | — | — |
| 2017 | — | −$1,456 | $26.40 | −$753.47 | — | — |
| 2019 | — | $335,325,450 | — | $280,164,239 | — | — |
| 2020 | — | $2,691,598,650 | — | $2,571,551,006 | — | — |
| 2024 | $1.21 | −$2.02 | — | −$2.05 | — | $4.50 |
| 2025 | $0.44 | −$2.98 | — | −$2.59 | — | $1.97 |